Dendritic cells (DCs) are considered to be the most potent antigenpresenting cells (APCs) for inducing adaptive immune responses 1 . APCs present peptides derived from cytosolic antigens bound to major histocompatibility complex (MHC) class I and exogenous antigens on MHC class II molecules for recognition by CD8 + T cells and CD4 + T cells, respectively 2 . However, DCs also have the ability to present peptides derived from exogenous internalized antigens on MHC class I molecules, a process referred to as 'cross-presentation' 3 . Cross-presentation, or cross-priming, is critical for the initiation of cytotoxic CD8 + T cell responses to tumor cells, bacteria or viruses that do not directly infect DCs 3, 4 .
Dendritic cells (DCs) are considered to be the most potent antigenpresenting cells (APCs) for inducing adaptive immune responses 1 . APCs present peptides derived from cytosolic antigens bound to major histocompatibility complex (MHC) class I and exogenous antigens on MHC class II molecules for recognition by CD8 + T cells and CD4 + T cells, respectively 2 . However, DCs also have the ability to present peptides derived from exogenous internalized antigens on MHC class I molecules, a process referred to as 'cross-presentation' 3 . Cross-presentation, or cross-priming, is critical for the initiation of cytotoxic CD8 + T cell responses to tumor cells, bacteria or viruses that do not directly infect DCs 3, 4 .
In most APCs, early endosomes or nascent phagosomes that contain newly internalized antigens undergo a maturation process in which the organelle pH is reduced and proteolytic capacity increases 5 . In DCs, however, this process needs to be carefully modulated, because extensive lysosomal proteolysis is incompatible with cross-presentation 6 and favors antigen presentation via MHC class II 7 . Partial degradation is thought to facilitate cross-presentation by allowing ingested antigens to escape the endocytic or phagocytic pathways and enter the cytoplasm 8 , where further degradation by the proteasome occurs 9 . This is followed by translocation of the resulting antigenic peptides into the endoplasmic reticulum 10 , or perhaps into phagosomal or endosomal compartments 11 , where they can bind to MHC class I molecules 12, 13 .
To sustain antigen stability, DCs exhibit a smaller capacity for phagosomal degradation than do macrophages, including limited lysosomal acidification 14 and low expression of lysosomal proteases 15 . These unique features endow DCs, particularly CD8α + DCs in the mouse, with a large capacity for cross-presentation both in vitro and in vivo 3 . However, after being stimulated by Toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS), DC phagosomes acquire mature lysosomal properties 14 , which shifts the balance toward the induction of MHC class II-restricted antigen presentation and a reciprocal decrease in cross-presentation 16 . Consistent with that, macrophages, known to have very large lysosomal degradative capacity, are generally less efficient in performing cross-presentation, while they can effectively present antigens via MHC class II 17 . Thus, lysosomal activity is a critical factor in determining the fate of an internalized antigen and in regulating the balance between the two exogenous antigen-presenting pathways in DCs. However, the underlying molecular mechanisms of this remain unclear.
The transcription factor TFEB transcriptionally regulates lysosomal biogenesis and function in a variety of cell types in response to various stimuli, such as growth factors and nutrients 18 . Expression analysis suggests that TFEB is a central regulator of cellular degradative pathways and, due to its role in stress responses, enhancement of TFEB activity has emerged as a potential therapeutic approach for various lysosomal and protein aggregation disorders 19 . TFEB positively regulates the expression of genes encoding molecules involved in phagocytosis, lipid catabolism and overall lysosomal function 19 . It is also activated during bacterial infection of macrophages 20 . However, the role of TFEB in antigen presentation has remained unclear. Here we found that this transcription factor was a key regulator of the presentation of exogenous antigen by APCs. Upregulation of TFEB expression during DC maturation led to enhanced lysosomal proteolytic activity, a reduction in cross-presentation and an increase 7 3 0 VOLUME 16 NUMBER 7 JULY 2015 nature immunology A r t i c l e s in presentation by MHC class II. Additionally, experimental downregulation of TFEB expression in macrophages led to an increase in MHC class I-restricted cross-presentation, which demonstrated a critical role for TFEB in regulating antigen presentation by APCs.
RESULTS

TFEB expression reduces cross-presentation in DCs
We first assessed the effect of TFEB on MHC class I-restricted crosspresentation in bone marrow-derived DCs (BMDCs) using ovalbumin (OVA) antigen. We retrovirally transduced DCs with vector expressing either TFEB tagged with enhanced green fluorescent protein (TFEB-EGFP) or EGFP alone (control-EGFP). The transduction efficiency was 80-85% for each experiment ( Supplementary  Fig. 1a) , and further purification of transduced BMDCs was not required. We incubated transduced and non-transduced BMDCs for 3 h with soluble OVA, then assessed the surface abundance of H-2K b molecules associated with the OVA-derived peptide SIINFEKL (residues 257-264) by confocal immunofluorescence microscopy through use of the monoclonal antibody 25.D1, which specifically recognizes H-2K b -SIINFEKL complexes on the surface of cells 21 . Non-transduced BMDCs had abundant H-2K b -SIINFEKL complexes on the cell surface, while H-2K b -SIINFEKL complexes were not detectable on the surface of TFEB-EGFP-transduced BMDCs (Fig. 1a) . However, after similar incubation with free SIINFEKL peptide (which binds in a processing-independent manner by simple exchange), H-2K b -SIINFEKL complexes were readily detectable on both TFEB-EGFP-transduced BMDCs and non-transduced BMDCs (Fig. 1a) . In a similar experimental set-up, we confirmed those results by flow cytometry assessing H-2K b -SIINFEKL on transduced (EGFP + ) BMDCs. BMDCs transduced with control-EGFP had surface H-2K b -SIINFEKL following incubation with soluble OVA, but BMDCs transduced with TFEB-EGFP did not (Fig. 1b,c) . After incubation of BMDCs with free SIINFEKL peptide, the amount of surface H-2K b -SIINFEKL was equally high on BMDCs transduced of BMDCs with control-EGFP and those transduced with TFEB-EGFP (Fig. 1d,e) . These data indicated that TFEB expression reduced the cross-presentation capacity of DCs.
Next we determined if TFEB affected the cross-presentationdependent stimulation of T cells. We incubated TFEB-EGFP-or control-EGFP-transduced BMDCs for 6 h with various concentrations of soluble OVA or OVA-coated latex beads, followed by incubation with B3Z hybridoma T cells, which specifically recognize H-2K b -SIINFEKL complexes, and assayed T cell activation by measuring production of interleukin 2 (IL-2). Cross-presentation by TFEB-EGFP-transduced BMDCs was inhibited much more than that by control-EGFP-transduced BMDCs for both soluble OVA (Fig. 1f) and OVA-coated beads (Fig. 1g) . The uptake of soluble OVA (Supplementary Fig. 1b ) and OVA-coated beads ( Supplementary  Fig. 1c) , SIINFEKL peptide-induced T cell activation (Fig. 1j) and surface abundance of H-2K b molecules (Fig. 1k,l) were all similar in TFEB-EGFP-transduced BMDCs and control-EGFP-transduced BMDCs, which indicated that the reduced cross-presentation observed in TFEB-overexpressing DCs was not due to defects in the uptake of antigen or expression of MHC class I. Transcription of TFEB-regulated genes depends on its localization to the nucleus 18 . We therefore assessed the effect of TFEB with an inactivated mutant nuclear-localization signal (TFEB(mNLS)) on cross-presentation 22 . Although BMDCs had equal expression of wildtype TFEB-EGFP and TFEB(mNLS)-EGFP ( Supplementary Fig. 1d ), cross-presentation by BMDCs transduced with TFEB(mNLS)-EGFP was comparable to that of BMDCs transduced with control-EGFP ( Fig. 1h) , which indicated that translocation of TFEB to the nucleus was required for inhibition of cross-presentation. We also assessed the cellular distribution of TFEB(mNLS) and wild-type TFEB in BMDCs incubated with opsonized OVA-coated beads. Transduced wild-type TFEB translocated to the nucleus within 30 min of the initiation of phagocytosis, while TFEB(mNLS) remained in the cytoplasm ( Supplementary  Fig. 1e ), which again demonstrated that translocation of TFEB to the nucleus was required for inhibition of cross-presentation.
To extend the analysis beyond the OVA-presentation system, we next determined whether TFEB was important for the crosspresentation of viral antigens. Glycoprotein B (gB) from herpes simplex virus type 1 (HSV-1) is a well characterized MHC class I antigen with a defined epitope that is recognized by CD8 + naive T cells. We incubated TFEB-EGFP-transduced BMDCs for 6 h with inactivated HSV-1 virus particles present in extracts of HeLa human cervical cancer cells, followed by overnight co-culture of the BMDCs with T cells enriched from the spleens of gBT mice, which have transgenic expression of an HSV-1-specific T cell antigen receptor. gBT CD8 + T cells recognize the immunodominant peptide of HSV gB resides 498-505, associated with H-2K b (ref. 23 ). TFEB-EGFP-transduced BMDCs were defective in stimulating gBT CD8 + T cells relative to the stimulatory ability of control-EGFP-transduced BMDCs (Fig. 1i) , which indicated that TFEB expression inhibited cross-presentation of the gB epitope. Together these data showed that activation of TFEB inhibited cross-presentation in BMDCs.
TFEB induces phagosomal acidification and proteolysis in DCs
Because TFEB is a transcriptional factor that regulates lysosomal functions 19 , we investigated whether its role in regulating crosspresentation might reflect an effect on the degradation of exogenous antigens. Analysis by immunofluorescence microscopy and flow cytometry indicated that that TFEB-EGFP-transduced BMDCs contained a larger number of lysosomal compartments than did control-EGFP-transduced cells ( Supplementary Fig. 2a,b) . TFEB is known to regulate lysosomal pH in other cell types 24 . To determine if TFEB induced the phagosomal acidification and degradation of internalized particulate antigens, we used a flow cytometry-based technique. We incubated TFEB-EGFP-transduced BMDCs with polystyrene beads coated with OVA conjugated to the pH-sensitive dye pHrodo succinimidyl ester or to the pH-insensitive dye Alexa Fluor 647 and allowed the BMDCs to ingest the beads for 60 min. As shown by confocal microscopy, beads coated with OVA conjugated to the pH-sensitive dye pHrodo fluoresced only in BMDCs containing TFEB-EGFP and not in cells lacking TFEB-EGFP (Fig. 2a) . Next we exposed TFEB-EGFP-and control-EGFP-transduced BMDCs to the beads noted above and performed the same experimental procedure with or without chloroquine, which neutralizes lysosomes. We then (Fig. 2b,c) . We determined the mean fluorescence intensity for each dye and used those results to calculate pH as follows: the ratio of the fluorescence intensity of the pH-sensitive dye to that of the pH-insensitive dye reflects the environmental pH. We estimated the pH of the phagosomes containing OVA-coated beads by comparing the mean fluorescence intensity values to a standard curve (Supplementary Fig. 3a ).
BMDCs transduced with control-EGFP had a high phagosomal pH (~7.2) (Fig. 2d) , as shown before 25 . However, the phagosomes of BMDCs transduced with TFEB-EGFP were much more acidic (pH, ~5.8) (Fig. 2d) . Chloroquine impaired the TFEB-induced acidification (Fig. 2c,d ). Phagosomes in macrophages have a much lower pH than that of phagosomes in DCs 25 , but those in TFEB-EGFPtransduced BMDCs were less acidic than those in macrophages (Fig. 2e) .
In control-EGFP-transduced BMDCs, the pH remained relatively unchanged over time, while the phagosomal pH continuously decreased after 15 min in TFEB-EGFP-transduced BMDCs (Fig. 2f) . This was consistent with the active induction of acidification by TFEB; it probably enhanced expression of the subunits of the vacuolar ATPase responsible for acidification 26 .
We next assessed the TFEB-mediated induction of genes encoding lysosomal proteases in BMDCs by quantitative RT-PCR. Expression of mRNA encoding lysosomal cathepsins D, L and S, which are involved in lysosomal antigen degradation in APCs, was substantially upregulated by TFEB expression (Fig. 2g) . However, TFEB expression had no effect on the expression of mRNA encoding LMP2, an interferon-γ-inducible immunoproteasome subunit, or of mRNA encoding TAP2, a subunit of the dimeric peptide transporter TAP, which translocates proteasomally generated peptides into the endoplasmic reticulum for loading onto MHC class I 2, 27 (Fig. 2g) . To evaluate the functional consequences of TFEB overexpression in BMDCs, we used a flow cytometry-based assay to monitor phagosomal degradation. After BMDCs ingested OVAcoated polystyrene beads by phagocytosis, we lysed the BMDCs and assessed the intact residual OVA by flow cytometry with a polyclonal OVA-specific antibody. We observed significantly less residual OVA on beads internalized by TFEB-EGFP-transduced BMDCs than on beads internalized by control-EGFP-transduced BMDCs (Fig. 2h,i) . OVA degradation in BMDCs was almost completely blocked by chloroquine (Fig. 2h,i) . To directly address whether the role of TFEB in cross-presentation was mediated by the induction of lysosomal activity, we inhibited lysosomal acidification or degradation in TFEB-EGFP-transduced BMDCs. Treatment with bafilomycin, an inhibitor of endosomal acidification, increased cross-presentation by control-EGFP-transduced BMDCs and partially restored cross-presentation by TFEB-EGFP-transduced BMDCs, as evaluated by the activation of T cells (Fig. 2j) ; this suggested that TFEB inhibited cross-presentation by increasing lysosomal acidification. We also obtained similar results with the lysosome-neutralizing agent chloroquine ( Supplementary  Fig. 4b ). Collectively, these data showed that TFEB expression in DCs enhanced antigen degradation in the phagosomes by inducing the expression of lysosomal proteases and phagosomal acidification.
TFEB inhibits cross-presentation induced by DC maturation LPS and other TLR ligands induce the maturation of immature DCs to mature DCs 28 . One of the most distinct differences between immature DCs and mature DCs in vitro is that immature DCs are extremely efficient in cross-presentation but present MHC class II-restricted antigens poorly, while mature DCs are less efficient at crosspresentation but have a large capacity for MHC class II presentation 29 . Lysosomal function and acidification changes induced by DC maturation constitute the main regulators of these presentation pathways 14, 15 . We therefore addressed whether activation of TFEB was responsible for the changes in cross-presentation capacity induced by DC maturation. The activation of TFEB is regulated by phosphorylation, which results in its translocation to nucleus. We observed more translocation of TFEB to the nucleus in LPS-treated BMDCs than in untreated BMDCs (Fig. 3a,b) , similar to published observations of corneal cells 30 . The activation of TFEB and its localization to nucleus exert a positive effect on its own transcription through an autoregulatory loop 26 , and we also found that stimulation of BMDCs for 6 h with LPS induced upregulation of the expression of Fig. 1f,g ).
(h) Stimulation of T cells via cross-presentation by wild-type BMMs left untreated (UT) or treated with TFEB-specific shRNA alone (KD) or followed by reconstitution of TFEB (KD + TFEB) (assessed as in Fig. 1f,g ). (i) Phagosomal pH in BMMs treated with control or TFEB-specific shRNA. *P < 0.05 and ** P < 0.005 (Student's t-test). Data are from at least three independent experiments with at least three mice per group in each (mean and (Supplementary Fig. 4a ) and TFEB protein 30 (Fig. 3c) .
We also assessed the regulation of TFEB expression in BMDCs in response to stimulation with other TLR ligands. TFEB was upregulated by exposure to crude Salmonella LPS, a TLR4 ligand, but was also upregulated by the TLR2 ligands peptidoglycan and lipoteichoic acid ( Supplementary Fig. 4b,c) , consistent with published data showing that infecting macrophages with S. aureus leads to activation of TFEB 20 . However, the dinucleotide CpG, a TLR9 ligand, had no effect on TFEB expression (Supplementary Fig. 4b,c) . We next determined if loss of endogenous TFEB regulated cross-presentation by analyzing the effect of short hairpin RNA (shRNA)-mediated silencing of Tfeb on both maturation-induced lysosomal activity and cross-presentation by BMDCs. TFEB-specific shRNA reduced the basal expression of TFEB mRNA but, more notably, the induction of TFEB mRNA expression in LPS-treated BMDCs was almost threefold lower than that in DCs expressing control (non-targeting) shRNA, as shown by quantitative RT-PCR (Fig. 3d) . Knockdown of TFEB had no effect on the LPS-induced maturation of BMDCs, as assessed by surface expression of the costimulatory molecule CD86 (B7-2) (Supplementary Fig. 4d ). Treating DCs with LPS for 24 h significantly decreased cross-presentation and increased phagosomal acidification in BMDCs transduced with control vector (Fig. 3e-g ), consistent with published results 28 . Silencing Tfeb inhibited LPS-induced acidification in BMDCs (Fig. 3e,f) and, in agreement with that, the LPS-mediated decrease in cross-presentation was partially restored in BMDCs in which TFEB was knocked down (Fig. 3g) . Silencing of Tfeb had a minor effect on the cross-presentation ability of immature DCs (Fig. 3g) . Reconstitution of TFEB expression by transduction of TFEB-EGFP into BMDCs in which TFEB was knocked down restored the inhibition of cross-presentation, while expression of the TFEB(mNLS) failed to do so (Fig. 3g) . Conversely, silencing expression of Tfeb in bone marrow-derived macrophages (BMMs) (Supplementary Fig. 5a ), which are poor cross-presenting cells, enhanced their ability to cross-present OVA relative to that of cells transduced with control shRNA (Fig. 3h) , while it simultaneously increased their phagosomal pH (Fig. 3i) . Reconstitution of TFEB expression in BMMs in which TFEB was knocked down reduced cross-presentation to its original levels (Fig. 3h) . BMMs Fig. 1f,g ). (b) Stimulation of T cells via cross-presentation of MHC class II by BMDCs transduced with control or TFEB-specific shRNA or with wild-type TFEB and treated with LPS (+ LPS) or not (− LPS) (assessed as in Fig. 1f,g ). (c) Confocal microscopy analyzing MHC class II on the surface of a BMDC transduced with TFEB-EGFP and a non-transduced BMDC, treated with LPS or not (left margin), assessed with an antibody specific to I-A b portion of MHC class II. Fig. 1f,g ).*P < 0.05 (Student's t-test). Data are from at least three independent experiments with at least three mice per group in each (mean and s.d. in a,b,e,f). Fig. 5b,c) . Overall, these data demonstrated that increased TFEB expression had a major role in regulating the reduction in cross-presentation observed after the maturation of BMDCs and suggested a crucial role for TFEB-mediated lysosomal activation in determining the general capacity of APCs for cross-presentation (Supplementary Fig. 6 ).
(d) Flow cytometry analyzing MHC class II on BMDCs transduced with control-EGFP or TFEB-EGFP and treated with LPS (+ LPS) or not (-LPS). (e) Mean fluorescence intensity of MHC class II on cells as in d. (f) Stimulation of T cells by wild-type BMMs left untreated (UT) or treated with TFEBspecific shRNA alone (KD) or followed by reconstitution of TFEB (KD + TFEB) (assessed as in
TFEB regulates MHC class II-restricted antigen presentation
Because lysosomal proteolysis has a well-characterized role in MHC class II-restricted antigen processing and presentation 31 , we sought to determine whether, in contrast to its role in inhibiting crosspresentation, the TFEB-mediated increase in lysosomal activity would enhance the presentation of antigen by MHC class II in BMDCs. For this, we used BMDCs transduced with TFEB-EGFP or control-EGFP and BMDCs in which TFEB was knocked down. We incubated these BDMCs for 6 h with various concentrations of hen egg lysozyme (HEL)-coated beads. We assayed processing and presentation by measuring the production of IL-2 by the T cell hybridoma BO4, which is specific for a peptide of HEL residues 74-88 in association with the MHC class II molecule I-A b . MHC class II-restricted presentation of HEL was significantly greater in TFEB-EGFP-transduced BMDCs than in control-EGFP-transduced BMDCs (Fig. 4a) . Conversely, HEL presentation was significantly lower in BMDCs in which TFEB was knocked down than in cells treated with control shRNA (Fig. 4b) , which suggested that the normal maturation-dependent increase in the presentation of antigen by MHC class II was inhibited by silencing of Tfeb in BMDCs. In addition to its role in lysosomal degradation, TFEB is also involved in the fusion of lysosomes with the plasma membrane (lysosomal exocytosis) 32 , a process known to be involved in the delivery of lysosomal MHC class II to the cell surface in response to LPS 33 . Consistent with such a role, we observed that BMDCs transduced with TFEB-EGFP had higher expression of MHC class II on their surface than did nontransduced or control-EGFP-transduced cells (Fig. 4c-e) , while the upregulation of MHC class II expression that is normally observed on BMDCs upon LPS-induced maturation 33 was further enhanced by the transduction of TFEB-EGFP (Fig. 4c-e) . In addition, I-A b -restricted HEL presentation was significantly lower BMMs in which TFEB was knocked down than in cells treated with control shRNA (Fig. 4f) , consistent with the dependence of steady-state lysosomal proteolytic activity on TFEB expression in these cells. Collectively, these data indicated a critical role for TFEB in regulating the processing of exogenous antigens by DCs and macrophages (Supplementary Fig. 6 ).
TFEB modulates cross-presentation in vivo
There are many DC subsets with different dedicated functions 34 . It is not clear how these differences are established, but certain factors, such as the cellular environment or maturation and activation state, are probably involved. In mice, lymphoid organ-resident CD8α + DCs have been defined as the most efficient cross-presenting cells in vivo 35 . Given that our experiments showed that TFEB negatively regulated cross-presentation, we hypothesized that splenic CD8 + DCs would have lower TFEB expression at steady state than would other APCs. By flow cytometry, CD11c + CD8 + cells constituted 8% of the total splenic DC population, while CD11c + CD4 + cells represented 13% (Fig. 5a) . Consistent with our hypothesis, CD11c + CD8 + DCs in the spleen had much lower expression of TFEB than did CD11c + CD4 + DCs, and splenic CD11b + macrophages had higher expression of TFEB than did CD11c + CD4 + DCs (Fig. 5b-d) , which would probably explain the substantial degradative capacity of macrophage lysosomes. Consistent with that suggestion, BMMs had much higher expression of TFEB mRNA than did BMDCs (Supplementary Fig. 5d ). Together our data suggested that the reduced expression of TFEB in CD8 + DCs was probably a contributing factor in their superior cross-presentation capacity relative to that of macrophages and other DC subsets.
Cross-presentation is critical for the induction of an in vivo response by naive CD8 + T cells, known as 'cross-priming' . To determine if expression of TFEB by DCs has a role in cross-priming, we used transgenic CD11c-DTR mice, in which administration of diphtheria toxin ablates the CD11c + population 36 . We adoptively transferred BMDCs transduced with TFEB-EGFP or TFEB(mNLS)-EGFP into CD11c-DTR mice depleted of CD11c + cells, at 24 h after injection of diphtheria toxin. To assay cross-priming, we immunized the mice the next day with soluble OVA and maintained the number of endogenous CD11c + DCs at a low level by additional injections of diphtheria toxin on days 3 and 6 (ref. 36). At 5 d after immunization with OVA (day 8 overall), almost all splenic DCs were EGFP + (donor derived), as assessed by immunohistochemistry and flow cytometry (Fig. 6a,b) . We evaluated the priming of OVA-specific CD8 + T cells in these mice at day 5 by flow cytometry with H-2K b -SIINFEKL tetramers. We observed over twofold fewer OVAspecific CD8 + T cells in mice reconstituted with DCs expressing npg A r t i c l e s TFEB-EGFP than in mice reconstituted with DCs transduced with TFEB(mNLS)-EGFP or control-EGFP (Fig. 6c,d ). These data indicated that TFEB expression diminished the ability of DCs to mediate cross-priming of CD8 + T cells in vivo.
DISCUSSION
Here we have established a critical role for the transcription factor TFEB in the regulation of antigen processing and presentation. In DCs, the activation of TFEB and its translocation to the nucleus substantially downregulated MHC class I-restricted antigen crosspresentation and cross-priming of naive CD8 + T cells while upregulating the processing and presentation of antigen by MHC class II. We observed a role for TFEB in regulating the cross-presentation of two different antigens-the model antigen OVA associated with beads, and necrotic HSV-1-infected cells-which indicated that the functional modifications induced by its expression were not specific to a particular antigen. We suggest that TFEB acts as a molecular switch that regulates the favored mode of presentation of exogenous antigens, and our data indicated that this was a result of a TFEBinduced increase in the expression of lysosomal proteases coupled with increased acidification. This unique function of TFEB probably allows DCs to respond rapidly to environmental stimuli and appropriately regulate the dynamics of antigen presentation. Although the function of TFEB in vivo may be more relevant to DCs, silencing Tfeb expression in DCs and macrophages demonstrated that the two pathways were regulated differentially in these cell types.
In the mouse, cross-presentation in vivo is largely a property of the CD8α + subclass of DCs and dermal migratory CD103 + DCs 3 . Efficient cross-presentation has been correlated with a reduction in lysosomal and phagosomal proteolysis and maintenance of a high vacuolar pH relative to that of macrophages 28 . Our data indicated that for CD8α + DCs, their lower TFEB expression than that of macrophages and CD4 + DCs had a major role in the maintenance of this 'subdued' lysosomal phenotype. The maturation of DCs has variable effects depending on the stimulus and the DC subset under investigation 37 . Upon phagocytosis, CD8α + DCs maintain their high phagosomal pH by GTPase Rac2-mediated recruitment of the NADPH oxidase Nox2 to the phagosome and the consequent alkalinization of the organelle by reactive oxygen species 25 . This probably works in parallel with TFEB and might explain why we did not observe similar levels of acidification in DCs and macrophages transduced to express TFEB. Human tonsillar DCs have been found to be competent for cross-presentation regardless of their surface phenotype 38 ; future studies should assess TFEB expression in these cell types.
The relative ability of DCs to mediate cross-presentation or presentation by MHC class II depends on their maturation state. Many stimuli can induce maturation, including microbial components, cytokines or even physical disruption in vitro or tissue damage in vivo 39 . Our experiments suggested that in mouse BMDCs, TFEB was rapidly activated and translocated to the nucleus after treatment with LPS. The outcome of activation of TFEB was a decrease in lysosomal pH and an increase in the expression of lysosomal proteases, which indicated that TFEB controlled a precise transcriptional program. Whether components of this program other than the regulation of protease expression and lysosomal acidification contribute to the differential effects on cross-presentation and MHC class II-restricted presentation remains to be determined. The upstream signaling factors and events that lead to the activation and expression of TFEB are unknown, but one potential mediator is protein kinase C (PKC). During osteoclast differentiation, PKC-induced phosphorylation of the carboxy-terminal region of TFEB has been shown to increase its activity 24 . Certain isoforms of PKC have shown to be involved in LPS-mediated cell responses [40] [41] [42] . In addition, activation by PKC has been shown to increase MHC class II antigen presentation by DCs 43 , which we demonstrated was TFEB dependent. TFEB is also regulated by the metabolic checkpoint kinase complex mTORC1 in the context of nutritional stress 44 , but at present there is no obvious connection between that and the TFEB-dependent effects we have reported here.
TFEB may be involved in MHC class II antigen-presentation pathways at multiple levels in addition to its role in increasing the degradative functions of lysosomes. TFEB expression was upregulated in response to a specific set of ligands involved in antibacterial responses (ligands for TLR2 and TLR4) but not in response to a ligand involved in antiviral responses (a ligand for TLR9), which suggested that TFEB expression might be particularly important for initiating the response of CD4 + T cells to bacterial infection. However, TFEB also upregulates genes encoding autophagy-related molecules 19 that are known to capture cytosolic antigens and deliver them to lysosomes for presentation by MHC class II, so the possibility of a role in the anti-viral CD4 + T cell response cannot be excluded 45 . In addition to enhancing lysosomal acidification and protease expression, the activation of TFEB also induces the trafficking of MHC class II molecules to the cell surface. This could potentially occur through the lysosomal calcium channel TRPML1, which is induced by TFEB and is involved in lysosomal exocytosis 46, 47 and the trafficking of MHC class II molecules to the cell surface in macrophages 48 . The induction of lysosomal biogenesis by TFEB in DCs might also result in more efficient and rapid phagolysosome generation and enhanced MHC class II-restricted processing of antigens taken up by phagocytosis.
Understanding how lysosomal activation regulates antigenpresentation pathways could contribute to the understanding of how DCs might regulate both immunity and peripheral tolerance.
Additionally, understanding what regulates the activation of lysosomal function in APCs will add considerably to the understanding of what initiates immune responses. Several studies have identified small molecules that activate TFEB in vitro 49 . Such molecules and any additional activators or inhibitors of TFEB that are generated might regulate antigen presentation in the context of different diseases and might provide opportunities for future drug development.
METHODS
Methods and any associated references are available in the online version of the paper. reprints and permissions information is available online at http://www.nature.com/ reprints/index.html.
the other was determined. The mean fluorescence intensity values were then compared with a standard curve obtained by resuspension of the cells that had phagocytosed beads for 1 h in solutions resembling intralysosomal ionic composition but of varying pH (ranging from a pH of 3 to a pH of 8) and containing 0.1% Triton X-100. The cells were then analyzed by flow cytometry to determine the emission ratio of the two fluorescent probes.
Flow cytometry. Cell-surface markers were stained for 30 min at 4 °C with the following monoclonal antibodies and the appropriate isotype-matched control antibodies (all from BD Biosciences): anti-CD86 (553692), anti-CD4 (553650), anti-CD8 (553040), anti-CD11c (550261), anti-CD11b (553311) and anti-CD19 (550992). The monoclonal antibody to I-A b (16-5321) was from Affymetrix. H-2K b associated with the OVA peptide SIINFEKL was detected with monoclonal antibody 25.D1 (14-5743; eBiosciences). TFEB was detected in fixed and permeablized cells with anti-TFEB (MBS004492) from MyBioSource; data were collected on an Accuri flow cytometer system (BD Biosciences) and were analyzed with FlowJo software.
Depletion and adoptive transfer of DCs. CD11c-DTR mice were given injection of diphtheria toxin (10 ng per gram of body weight, suspended in PBS) on day 1. 24 h later, mice were given intravenous injection of 1 × 10 6 BMDCs transduced with the vector control-EGFP, TFEB-EGRP or TFEB(mNLS)-EGFP. The next day, mice were immunized by injection of 200 µg of OVA protein adsorbed onto aluminum hydroxide adjuvant. 5 d after immunization with OVA, the spleen of each mouse was collected and single-cell suspensions were produced. So that low numbers of endogenous CD11c + cells could be maintained throughout the experiment, every 3 d mice were given injection of a low dose of diphtheria toxin (4 ng per gram of body weight, suspended in PBS). In vivo priming was evaluated by staining of the splenocytes for 1 h on ice with phycoerythrin-conjugated H-2K b -SIINFEKL tetramer and FITCconjugated anti-CD8β (553040; BD). The frequency of CD8 + cells positive for H-2K b -SIINFEKL was determined by flow cytometry.
Fluorescence staining, confocal microscopy and immunohistochemistry. The surfaces of non-permeablized DCs were stained for 2 h at 4 °C with monoclonal antibody to H-2K b (14-5743; eBiosciences) and monoclonal antibody to I-A b (16-5321; Affymetrix), each at a dilution of 1:100, for detection of the translocation of MHC class I and MHC class II molecules to the cell surface. Cells were washed, were fixed with 1% PFA and then were processed for microscopy. LAMP-1 on fixed and permeabilized DCs was stained with anti-LAMP-1 (1D4B; Iowa Hybridoma Bank). All samples were analyzed with a Leica TCS SP2 confocal microscope. Immunohistochemistry was performed on slice sections 5 µm in thickness prepared from paraffin-embedded spleen tissues with a microtome.
Real-time PCR. Total RNA was extracted from cells with an RNAase MiniKit according to the manufacturer's protocol (Qiagen). First-strand cDNA was synthesized with an AffinityScript Multi Temperature cDNA synthesis kit according to the manufacture's protocol (Agilent Technologies). Quantitative PCR analysis was performed with SYBER Select Master Mix (Invitrogen) and forward and reverse primers (Supplementary Table 1) for the detection of gene expression.
Phagocytosis assay. DC (2.5 × 10 6 cells per ml) were incubated for 1 h at 37 °C at a ratio of 1:5 with beads 3 µm in diameter coated with Alexa Fluor 647-conjugated OVA. Samples were then pelleted at 1,200 r.p.m. for 5 min and were washed twice with cold PBS. Samples were then resuspended in flow cytometry buffer (PBS containing %5 FBS) and were transferred to a 96-well plate with V-bottomed wells. After blockade of Fc receptors (Mouse BD Fc Block), extracellular beads were stained with rabbit anti-OVA (SAB5300165; Sigma), followed by goat anti-rabbit F(ab′) 2 (553142; BD) and then were fixed in 2% PFA in PBS. Particle uptake was quantified by flow cytometry with gating on DCs. In a parallel experiment, the DCs were incubated for 15 min with cytochalasin D and were maintained in cytochalasin D for inhibition of phagocytosis.
Silencing of Tfeb. TFEB-specific shRNA (CCGGCCAAGAAGGATCTGGAC TTAACTCGAGTTAAGTCCAGATCCTTCTTGGTTTTTG; clone ID NM_ 011549.2-1526s1c1, TRCN0000085549; Mission shRNA; Sigma) specifically designed for lentiviral delivery was used.
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